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Abstract: Amlodipine is a long-acting, dihydropyridine calcium antagonist now widely used 
for lowering of elevated blood pressure. In recent years it has been shown to be effective in 
reducing both blood pressure and risk of cardiovascular (CV) events when used in combina-
tion with other antihypertensive agents of different classes. Strong evidence of cardiovascular 
benefit has been attained for combination of amlodipine with diuretics or angiotensin converting 
enzyme (ACE) inhibitors in a number of high-risk CV groups, including those with established 
coronary artery disease, diabetes, and at risk of renal disease. Combination therapies of amlo-
dipine with other agents eliciting renin-angiotensin-aldosterone system blockade (angiotensin II 
receptor blockers or renin inhibitors) have been shown to be effective blood pressure-lowering 
strategies, but await the results of ongoing trials for direct evidence of benefit for renal disease 
progression and CV morbidity and mortality.
Keywords: hypertension, amlodipine, cardiovascular disease, calcium antagonist, 
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Introduction
The most widespread clinical use of calcium channel blockers or calcium antagonists 
is in the management of elevated blood pressure (BP). The BP-lowering effects of 
this class of drugs are mediated by binding to calcium channels which inhibits the 
transmembrane influx of calcium into vascular smooth muscle cells and cardiac muscle 
cells. As calcium influx drives contractile activity of these muscle cells, the resultant 
lowering of cytosolic free calcium elicits potent peripheral arterial vasodilatation, and 
in the heart results in increased blood flow to cardiac muscle. Amlodipine is a third 
generation dihydropyridine calcium antagonist which demonstrates high selectivity for 
vascular smooth muscle, with minimal impact upon heart rate, and no negative ionotro-
pic effects or electrophysiological disturbances. In addition to its antihypertensive and 
antianginal properties, amlopidine has also been suggested to inhibit vascular smooth 
muscle cell proliferation and exhibit antiatherosclerotic effects. Amlodipine has a high 
bioavailability, higher volume of distribution, and prolonged half-life compared to 
other calcium antagonists making it more suitable for once a day administration.1
Amlodipine in prevention of cardiovascular disease
The advantage of a longer duration of antihypertensive effect for amlodipine over 
short-acting calcium antagonists raised the question of how it compared to other first-
line antihypertensive agents in reducing the risk of cardiovascular disease (CVD). 
Evidence from the early trials was inconsistent. Trials such as the Treatment of Mild 
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Hypertension Study (TOMHS) found amlodipine was as 
effective as other commonly used classes of hypertensive 
agent in preventing cardiovascular events.2 Conversely, 
the Fosinopril versus Amlodipine Cardiovascular Events 
Trial (FACET) in patients with hypertension and diabetes 
reported that despite amlodipine having a greater antihyper-
tensive effect, there was a significantly lower rate of major 
vascular events in the fosinopril group compared to the 
amlodipine group (hazard ratio [HR]: 0.49; 95% confidence 
interval [CI]: 0.26–0.95; P = 0.03).3 This uncertainty was 
reflected in two meta-analyses published in the Lancet in 
2000 raising great debate around the role of calcium chan-
nel blockers as first-line therapy in hypertension. The first 
meta-analysis by Pahor and colleagues (n = 27,743) con-
cluded that intermediate/long-acting calcium antagonists 
were inferior to other antihypertensive therapies in the 
prevention of major cardiovascular events.4 Conversely, 
the second meta-analysis undertaken by the Blood Pressure 
Lowering Treatment Trialists’ Collaboration (n = 74,696) 
found no superiority nor inferiority of calcium antagonists 
compared to other antihypertensive agents for reducing 
major cardiovascular events.5 Further research was clearly 
needed to establish the relative cardiovascular benefit 
of amlodipine in hypertension, but also within high-risk 
subgroups such as those with diabetes, renal disease, older 
individuals, and ethnicities known to be at higher CVD risk 
(such as African Americans,6 Australian Aboriginals,7 and 
South Asians living in the UK).8
In the first decade of this century a number of large scale 
clinical trials have informed our understanding of the effect 
of amlodipine on risk of cardiovascular disease. Over this 
period there has also been a shift in focus toward the use 
of amlodipine as part of a multiple-antihypertensive agent 
approach to treatment of high blood pressure.
Landmark trials in patients  
at elevated risk of CVD
The Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT) enrolled 33,357 
participants aged over 55 years with hypertension and at 
least one coronary heart disease (CHD) risk factor in a 
randomized, double-blind trial comparing three antihyper-
tensive interventions; a calcium antagonist (amlodipine), an 
angiotensin converting enzyme (ACE)-inhibitor (lisinopril), 
and a diuretic (chlorthalidone). With a mean follow up of 
4.9 years, ALLHAT found no difference in the primary out-
come (combined fatal CHD or nonfatal myocardial infarction) 
between the amlodipine and diuretic groups (relative risk 
[RR]: 0.98, 95% CI: 0.90–1.07; P = 0.65; Figure 1).9 The 
size and quality of the ALLHAT trial design provided con-
vincing evidence to refute the suggestions that amlodipine 
might be inferior in reducing major cardiovascular events, 
and the lack of any difference between amlodipine and 
diuretic on the primary outcome was consistent across risk 
subgroups (based upon age, sex, race, diabetes). However, 
compared to the thiazide diuretic, amlodipine was associ-
ated with an increased 6-year risk of heart failure (RR: 1.38, 
95% CI: 1.25–1.52; P < 0.001).9
In patients with established coronary artery disease, 
the Prospective Randomized Evaluation of the Vascular 
Effects of Norvasc Trial (PREVENT) undertook a placebo-
controlled trial of amlodipine to determine the effect upon 
atherosclerotic progression. PREVENT found no effect of 
amlodipine on mean minimal vessel diameter, but noted 
a significant effect of amlodipine in slowing the progres-
sion of carotid artery atherosclerosis. There was however 
no effect of amlodipine on rates of all-cause mortality or 
cardiovascular events.10 However in the CAMELOT study, 
which compared amlodipine or enalapril vs placebo in 
patients with coronary artery disease but with normal blood 
pressure, amlodipine was shown to be associated with a 
reduced risk of adverse cardiovascular events. The trend 
towards a slowing of atherosclerosis progression was only 
significant in those with higher systolic blood pressure.11
The Valsartan Antihypertensive Long-term Use Evalua-
tion (VALUE) trial compared amlodipine to the angiotensin 
receptor antagonist valsartan in 15,245 patients over 50 years 
of age with hypertension and high risk of CVD.12 VALUE 
found no difference between the two groups in the compos-
ite cardiac morbidity and mortality endpoint, despite blood 
pressure being lowered to a greater extent by amlodipine. In 
analysis of the secondary endpoints, myocardial infarction 
(MI) was significantly more frequent in the valsartan group 
(HR: 1.19, 95% CI: 1.02–1.38; P = 0.02), but there were 
significantly fewer cases of new-onset diabetes in the val-
sartan group compared to the amlodipine group (HR: 0.77, 
95% CI: 0.69–0.86; P , 0.001). The results of VALUE also 
highlighted the difficulty in achieving BP targets with anti-
hypertensive monotherapy. Upon completion of the study, 
or reaching a primary endpoint, only 35% of the amlodipine 
group and 27% of the valsartan group remained on their 
randomized single-agent therapy (with predefined schedules 
for treatment intensification in order to meet blood pressure 
targets in-study).
Trials such as VALUE, amongst others, highlighted 
that the majority of patients require more than one 
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  antihypertensive agent to reach blood pressure targets.12 
The question of what represents the optimal combination of 
antihypertensive agents has been addressed by a number of 
large scale studies including the Anglo-Scandinavian Cardiac 
Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-
BPLA). ASCOT-BPLA was a prospective randomized con-
trolled trial in 19,257 patients with hypertension plus at least 
three other CVD risk factors.13 Participants were assigned 
to either amlodipine (+perindopril as required) or atenolol 
(+bendroflumethiazide as required). ASCOT-BPLA was 
stopped prematurely based upon the finding that compared 
to the amlodipine group, those in the atenolol group had 
significantly higher mortality and worse outcomes on a num-
ber of secondary endpoints. Although the primary outcome 
measure of nonfatal MI and fatal CHD failed to reach sig-
nificance (HR: 0.90, 95% CI: 0.79–1.02; P = 0.105), those on 
the amlodipine-based regimen had significantly lower rates 
of cardiovascular mortality (HR: 0.76, 95% CI: 0.66–0.89; 
P = 0.001) and total coronary events and procedures (HR: 
0.84, 95% CI: 0.78–0.90; P , 0.0001) than those on the 
atenolol-based regimen.
More recently, the Avoiding Cardiovascular Events 
through Combination Therapy in Patients Living with 
Systolic Hypertension (ACCOMPLISH) trial examined the 
combination of ACE-inhibitor (benazepril) plus amlodipine 
compared to benazepril plus the diuretic hydrochlorothiazide 
for the treatment of hypertension in 11,506 high CVD risk 
patients. With a primary endpoint encompassing CVD death, 
MI, stroke, angina, resuscitation after sudden cardiac arrest, 
and coronary revascularization, ACCOMPLISH found that 
the benazepril–amlodipine combination afforded signifi-
cantly greater protection against cardiovascular events than 
the benazepril–hydrochlorothiazide combination (RR: 0.80, 
95% CI: 0.72–0.90; P , 0.001).14
Amlodipine and heart failure
Treatment with short-acting calcium antagonists had been 
found to worsen heart failure and increase risk of death in 
patients with significant left ventricular dysfunction.15,16 
This was suggested to be due to the tendency of these 
shorter-acting calcium antagonists to depress cardiac 
contractility and activate neurohormonal systems. Whether 
amlodipine also increased morbidity and mortality in this 
patient group was addressed by the Prospective Random-
ized Amlodipine Survival Evaluation (PRAISE) study. 
PRAISE randomly allocated 1153 patients with chronic 
heart failure (HF) class IIIB or IV and a left ventricular 
ejection fraction of less than 30% to either placebo or 
amlodipine on top of usual therapy. Amlodipine was found 
not to adversely impact morbidity or mortality in this 
population of CHF patients (amlodipine vs placebo, RR: 
0.91, 95% CI: 0.76–1.10; P = 0.31).17 Upon examination of 
adverse effects, amlodipine was associated with increased 
risk of peripheral and pulmonary edema, but a reduced 
risk of uncontrolled hypertension. While the results of 
PRAISE suggested that amlodipine could be safely used 
in HF, there was no substantial mortality or morbidity 
benefit suggesting that their routine use would be limited 
in this patient group.
In those with hypertension but without overt heart failure, 
ALLHAT found that amlodipine was associated with an 
increased 6-year risk of heart failure compared to a thiazide 
diuretic (RR: 1.38, 95% CI: 1.25–1.52).9 However both the 
VALUE and the Candesartan Antihypertensive Survival 
Evaluation in Japan (CASE-J) studies found no differ-
ence in risk of heart failure for amlodipine compared with 
angiotensin receptor antagonists (valsartan vs amlodipine, 
HR: 0.89, 95% CI: 0.87–1.03; P = 0.12,12 and candesartan vs 
  amlodipine, HR: 1.25, 95% CI: 0.65–2.42; P = 0.50).18
Amlodipine and angina
Shorter-term trials have demonstrated the antianginal 
efficacy of amlodipine,19 thought to be mediated by the 
amlodipine-induced dilation of coronary arteries and reduc-
tion in total peripheral resistance, decreasing the occurrence 
of symptomatic angina, and silent MI. In the PREVENT 
trial those with a history of angina comprised 68% of the 
participant group, and compared to placebo, amlodipine 
significantly reduced hospitalization for unstable angina 
(HR: 0.67, 95% CI: 0.48–0.93).10 However whether amlo-
dipine offers a level of long term antianginal benefit beyond 
other antihypertensives remains unclear. In ALLHAT there 
was no significant difference in hospitalization/treatment 
for angina between the amlodipine and diuretic groups 
(RR: 1.02, 95% CI: 0.94–1.10).9 ACCOMPLISH found 
no effect of amlodipine in combination with benazepril 
vs benazepril + hydrochlorothiazide on hospitalization for 
unstable angina (HR: 0.75, 95% CI: 0.50–1.10). In ASCOT-
BPLA, amlodipine vs atenolol significantly reduced unstable 
angina (HR: 0.68, 95% CI: 0.51–0.92; P = 0.0115) but had 
no significant effect on chronic stable angina (HR: 0.98, 
95% CI: 0.81–1.19).13
Those with angina have had significant representation in 
outcome-driven trials of amlodipine and there is no evidence 
of diminished effectiveness of amlodipine for prevention of 
secondary CVD in this population group.
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antihypertensive therapeutic strategies for prevention of 
renal failure in addition to reducing risk of cardiovascular 
morbidity and mortality remain to be clarified, particularly 
within risk subgroups.
In primary agent comparisons, ALLHAT found no 
significant differences between amlodipine vs diuretic in 
the development of ESRD or renal disease progression 
(by estimated glomerular filtration rate [GFR]) in high risk 
hypertensive patients.9,22 CASE-J also noted no significant 
difference in rates of renal events between candesartan- and 
amlodipine-treated high-risk hypertensive patients (HR: 0.70, 
95% CI: 0.39–1.26; P = 0.23).18 The African American Study 
of Kidney Disease and Hypertension (AASK) randomized 
1094 African Americans with hypertension and renal insuf-
ficiency to either a beta-blocker (metoprolol), ACE-inhibitor 
(ramipril), or amlodipine and examined progression of renal 
disease over a 3–6 year follow-up.23,24 With a composite 
clinical endpoint comprising reduction in GFR, ESRD, or 
death, AASK found that compared to amlodipine, treatment 
with ramipril resulted in a 38% relative risk reduction in 
clinical events (RR: 0.62, 95% CI: 0.44–0.87; P = 0.005). 
In this study ramipril was also more effective than both 
amlodipine and metoprolol in slowing the rate of decline in 
GFR, supporting the use of renin-angiotensin system (RAS) 
blockade as an integral part of a strategy for blood pressure 
lowering in nephropathy.
Fixed dose combinations
What type of antihypertensive agent might best comple-
ment ACE-inhibition as part of a fixed combination treat-
ment was addressed in a prespecified secondary analysis 
of the ACCOMPLISH study.25 ACCOMPLISH found that 
using the progression of chronic kidney disease endpoint 
comprised of doubling of serum creatinine, ESRD, and 
dialysis, treatment with an ACE-inhibitor (benazepril) plus 
amlodipine was associated with significantly reduced risk 
of kidney disease progression compared to treatment with ACE-
inhibitor plus a diuretic (hydrochlorothiazide) (HR: 0.52, 95% 
CI: 0.41–0.65; P , 0.0001). Similar results were found 
for the composite endpoint of chronic renal disease 
plus cardiovascular death. Rates of peripheral edema were 
higher in the benazepril + amlodipine group, but rates of 
dizziness and hypotension were lower compared to the 
benazepril + hydrochlorothiazide group. ACCOMPLISH 
concluded that as part of an antihypertensive treatment 
strategy, benazepril + amlodipine offered significant 
benefit for preventing renal disease progression over 
benazepril + hydrochlorothiazide.
No. at risk
Chlorthalidone
Amlodipine
Lisinopril
15255
0
10
20
30
12 34
Time to event, y
Combined coronary heart disease
C
u
m
u
l
a
t
i
v
e
 
c
o
m
b
i
n
e
d
 
e
v
e
n
t
 
r
a
t
e
,
 
%
567
9048
9054
14211
8428
8347
13320
7940
7780
12415
7422
7264
10587
6357
6207
5804
3512
3461
2698
1672
1622
187
142
170
No. at risk
Chlorthalidone
Amlodipine
Lisinopril
15255
0
10
15
5
20
25
30
12 34
Time to event, y
All-cause mortality
C
u
m
u
l
a
t
i
v
e
 
e
v
e
n
t
 
r
a
t
e
,
 
%
567
9048
9054
14933
8847
8853
14584
8654
8612
14077
8391
8318
12480
7442
7382
7185
4312
4304
3523
2101
2121
428
217
144
Figure 1 Cumulative event rates in ALLHAT (Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial).9 
ALLHAT Research Group. JAMA 2002;288(23):2991. Copyright © (2002) American 
Medical Association. All rights reserved.
No. at risk
Chlorthalidone
Amlodipine
Lisinopril
15255
0
6
3
9
12
15
12 34
Time to event, y
Heart failure
C
u
m
u
l
a
t
i
v
e
 
e
v
e
n
t
 
r
a
t
e
,
 
%
567
9048
9054
14528
8535
8496
13898
8185
8096
13224
7801
7689
11511
6785
6698
6369
3775
3789
3016
1780
1837
384
210
313
Amlodipine and renal disease 
outcomes
Hypertension is a major cause of end stage renal disease 
(ESRD), and blood pressure levels have been shown to be 
correlated with renal disease progression.20,21 The optimal 
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Diabetes
Large scale studies such as ASCOT-BPLA have examined 
the effect of antihypertensive agents on new-onset diabetes 
in an at-risk cohort. ASCOT-BPLA found significantly fewer 
cases of new onset diabetes in the amlodipine/perindopril 
vs atenolol/thiazide diuretic antihypertensive regimen (HR: 
0.70, 95% CI: 0.63–0.78; P , 0.0001). Consistent with this, 
ALLHAT also noted that diuretics were associated with a 
greater number of cases of new onset diabetes compared to 
amlodipine (OR: 0.73, 95% CI: 0.58–0.91; P , 0.01). These 
studies highlighted a slightly increased risk of new onset 
diabetes with diuretics, although in both cases this increase 
in risk of diabetes did not translate to any measurable impact 
on cardiovascular disease risk.
In studies comparing amlodipine to angiotensin recep-
tor blockers, the VALUE study found significantly fewer 
Table 1 Characteristics of major amlodipine trials
Study (ref) Agents studied Disease state N Outcome measures
Single antihypertensive agent comparison trials
TOMHS2 Placebo vs chlorthalidone vs  
acebutolol vs doxazosin vs  
amlodipine vs enalapril
Mild hypertension 902 BP, CVD events
ALLHAT9 Chlorthalidone vs  
amlodipine vs lisinopril
Hypertension + $1 other  
CVD risk factor
33,357 CVD events, BP
PREVENT10 Placebo vs amlodopine Established coronary artery disease 825 CVD events, atherosclerotic 
disease progression
AASK24 Metoprolol vs  
amlodipine vs ramipril
Hypertensive renal disease 1094 Renal disease  
progression, BP
CAMELOT11 Amlodipine vs enalapril vs  
placebo
Established coronary artery disease +  
normal blood pressure
1991 CVD events
VALUE12 Valsartan vs amlodipine Hypertension at high CVD risk 15,245 CVD mortality and 
morbidity
CASE-J18 Candesartan vs amlodipine Hypertension at high CVD risk 4728 CVD mortality and  
morbidity, diabetes onset
FACET3 Fosinopril vs amlodipine Hypertension + diabetes 380 CVD events, BP
Combination antihypertensive agent therapy trials
ASCOT-BPLA13 Amlodipine ± perindopril vs  
atenolol ± bendroflumethiazide
Hypertension + $3 other  
CVD risk factors
19,257 Nonfatal MI, CVD mortality
PRAISE17 Amlodipine + ACEi + diuretic vs  
placebo + ACEi + diuretic
Heart failure 1153 Mortality, CVD morbidity
ACCOMPLISH14 Benzepril + amlodipine vs  
Benzepril + hydrochlorothiazide
Hypertension at high CVD risk 11,506 CVD mortality, CVD  
events, renal outcomes
Abbreviations: TOMHS, Treatment of Mild Hypertension Study; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; PREVENT, 
Prospective Randomized Evaluation of the Vascular Effects of Norvask Trial; AASK, African American Study of Kidney Disease and Hypertension; VALUE, Valsartan 
Antihypertensive Long-term Use Evaluation; CASE-J, Candesartan Antihypertensive Survival Evaluation in Japan; FACET, Fosinopril Versus Amlodipine Cardiovascular 
Events Randomized Trial; ASCOT-BPLA, Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm; PRAISE, Prospective Randomized Amlodipline Survival 
Evaluation; ACCOMPLISH, Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension.
Table 2 Amlodipine combinations
Combination agent Present level of evidence Evidence of benefit in:
Amlodipine
Plus Thiazide diuretics CV outcomes 
BP-lowering
Hypertension at high CVD risk
Plus ACE inhibitor CV outcomes 
BP-lowering  
Renal disease progression
Hypertension at high CVD risk 
Established CAD 
Diabetes
Plus ARB BP-lowering Hypertension
Plus Renin inhibitor BP-lowering Hypertension
Plus Beta-blocker BP-lowering Hypertension at high CVD risk
Plus Statin BP- (and lipid-) lowering Those at increased CVD risk  
due to hypertension + hyperlipidemia
Abbreviations: CV, cardiovascular; BP, blood pressure; ACE, angiotensin converting enzyme; CAD, coronary artery disease; CVD, cardiovascular disease; ARB, angiotensin II 
receptor blocker.
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cases of new-onset diabetes in the valsartan group compared 
to the amlodipine group (HR: 0.77, 95% CI: 0.69–0.86; 
P , 0.001).12 CASE-J noted a 36% relative risk reduction in 
new onset diabetes in the candesartan arm compared to the 
amlodipine arm (RR: 0.64, 95% CI: 0.43–0.97, P = 0.033).18 
Overall, trials to date suggest that amlodipine has little influ-
ence on new-onset diabetes.
Those with established diabetes are at greater increased 
risk of cardiovascular and renal disease, and management 
of hypertension in diabetes is crucial for reducing risk of 
events. With diabetes being a major CVD risk factor, this 
patient population often represents a significant subgroup 
within hypertension trials. In ACCOMPLISH, 60% of the 
study population had diabetes, and in this subgroup the supe-
riority of the benazepril/amlodipine combination over the 
benazepril/hydrochlorothiazide combination was consistent 
(HR: 0.79, 95% CI: 0.68–0.92; P = 0.003) with that seen in 
the whole study population14 (Table 2). Those with diabetes 
made up approximately 18% of the ASCOT-BPLA study pop-
ulation with the cardioprotective   superiority of   amlodipine 
retained amongst the diabetes subgroup (HR: 0.87, 95% 
CI: 0.76–0.99; P = 0.03).13
Other amlodipine combination 
therapies
Blood pressure-lowering efficacy has been shown for com-
binations of amlodipine with angiotensin receptor blockers26 
and renin inhibitors,27 and based upon the complementary 
mechanisms of action of these agents it would be logical to 
suggest that they would produce at least similar reductions 
in CVD risk. Trials examining effects of amlodipine/newer 
RAS blockade agents on CVD outcomes are underway and 
results pending.28
Conclusion
Amlodipine monotherapy has been shown to be not inferior 
to other antihypertensive agents in reducing blood pressure; 
however the majority of those with hypertension require 
more than one antihypertensive agent to achieve blood 
pressure control. Amlodipine appears to offer significant 
benefit as a second-line antihypertensive therapy, and may 
also influence CVD progression/development through 
BP-independent effects. The ACCOMPLISH study found 
that amlodipine in combination with an ACE-inhibitor 
reduces CVD mortality and morbidity, in addition to 
reducing progression of kidney disease. Whether combina-
tions using other agents eliciting RAS blockade (such as 
angiotensin receptor antagonists or renin inhibitors) offer 
the same benefits for preventing renal disease progression 
and CVD morbidity and mortality is under investigation 
in ongoing trials. Since the release of amlodipine in the 
early 1990s, it still remains one of the top five global 
pharmaceutical products with US$5 billion in sales in 
2006.29 Its effectiveness in lowering blood pressure in addi-
tion to high tolerability and minimal side effects has made 
it an agent of choice in both single and combination drug 
treatment strategies for reducing the burden of cardiovas-
cular disease across the globe.
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